Erasca, Inc.
Associate Director, Computational Chemistry
Steven Wilkens Consulting Feb 2017 - Mar 2019
Owner
Takeda California, Inc. Nov 2006 - Dec 2016
Senior Scientist
Kalypsys Mar 2005 - Oct 2006
Senior Scientist
Gnf Jul 2001 - Feb 2005
Principle Scientist
Education:
University of Wisconsin - Madison 1996 - 2001
Doctorates, Doctor of Philosophy, Biophysics
University of Minnesota 1991 - 1996
Bachelors, Bachelor of Science, Physics
Skills:
Drug Discovery Computational Chemistry Drug Design Life Sciences Biotechnology Lifesciences Biochemistry Machine Learning Structural Biology High Throughput Screening Java Medicinal Chemistry Cheminformatics Molecular Modeling Quantum Mechanics C++ Python R Web Development Virtual Screening Docking X Ray Crystallography Pharmacokinetics Systems Biology Bioinformatics Biomarkers
Wingate By Wyndham I95 N Feb 2011 - Oct 2011
General Manager
Fairfield Inn & Suites Feb 2011 - Oct 2011
General Manager
Courtyard Fort Worth West Cityview Mar 2009 - Mar 2010
General Manager
Skills:
Hospitality Management Budgets Hospitality Industry Leadership Hotels Hospitality Revenue Analysis Sales Hotel Management
Name / Title
Company / Classification
Phones & Addresses
Steven C. Wilkens President
MD PLUMBERS INC
7730 Herchel St, La Jolla, CA 92037 7730 Herschel Ave, La Jolla, CA 92037
- Osaka, JP Rongliang Chen - San Diego CA, US Betty Lam - San Diego CA, US Matthew Lardy - San Diego CA, US Srinivasa Reddy Natala - San Diego CA, US Steven James Wilkens - San Diego CA, US Mitsunori Kono - San Diego CA, US Zhe Nie - San Diego CA, US
Disclosed are compounds of Formula 1,and pharmaceutically acceptable salts thereof, wherein G, p, R, R, R, R, and Rare defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating disorders, diseases, and conditions involving the immune system and inflammation, including rheumatoid arthritis, cancer, and other disorders, diseases, and conditions for which inhibition of SYK is indicated.
Mark E. Adams - , US Rongliang Chen - San Diego CA, US Mitsunori Kono - Yokohama, JP Betty Lam - San Diego CA, US Matthew Lardy - San Diego CA, US Srinivasa Reddy Natala - San Diego CA, US Steven James Wilkens - San Diego CA, US Zhe Nie - San Diego CA, US
Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein G, p, R, R, R, R, and Rare defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating disorders, diseases, and conditions involving the immune system and inflammation, including rheumatoid arthritis, cancer, and other disorders, diseases, and conditions for which inhibition of SYK is indicated.